drugset / Trial / NCT03867188

Liposomal Bupivacaine (Exparel) in Sarcomas

NCT03867188

Phase 0 Terminated 2 enrolled Wake Forest University Health Sciences
Non-randomizedParallel-groupOpen-labelSupportive care

Summary

The purpose of this research is to study a medication called liposomal bupivacaine (EXPAREL®). Study doctors want to see if it is safe, if it can reduce pain after surgery, and the study doctor want to study its use after the removal a soft tissue tumor called a sarcoma

Timeline

Start
2019-01-14
Primary completion
2019-06-11
Completion
2019-06-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 20 ml
Subject Bupivacaine Other / unclassified 266 mg

Indications